Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Parnax Lab Limited is a pharmaceutical company based in India, specializing in the development and manufacturing of generic and specialty medications. The company benefits from a robust pipeline of products and a growing presence in international markets, particularly in Europe and North America, which drives its revenue growth.
Parnax Lab generates revenue primarily through the sale of generic pharmaceuticals, leveraging its cost-effective manufacturing processes and established distribution networks. The company maintains pricing power due to its focus on high-demand therapeutic areas and a diverse product portfolio.
Approval of new generic drugs by regulatory bodies like the FDA
Expansion into new international markets, particularly in Europe
Changes in pricing regulations affecting generic medications
Partnerships or collaborations with larger pharmaceutical companies
Regulatory changes impacting drug approval processes
Technological disruption in pharmaceutical manufacturing
Intensifying competition from other generic drug manufacturers
Potential for price erosion in key therapeutic areas
Moderate debt levels could impact financial flexibility
Negative free cash flow could limit investment in growth initiatives
moderate - The company's performance is somewhat linked to GDP growth and consumer spending, as healthcare expenditures tend to rise in stronger economic conditions.
The company's debt levels may increase financing costs if interest rates rise, potentially impacting profitability and investment in R&D.
minimal - Parnax Lab's operations are not heavily reliant on credit markets, given its current debt-to-equity ratio of 0.87.
growth - Investors are likely attracted to Parnax Lab due to its strong revenue growth and potential for market expansion.
moderate - The stock has shown some volatility, with a 3-month return of -18.6%, indicating sensitivity to market conditions.
